PLYX vs PMN

Polaryx Therapeutics, Inc. vs ProMIS Neurosciences Inc. — Valuation Comparison 2026

PLYX

Biotechnology
Polaryx Therapeutics, Inc.
Quality
4.3
out of 10
Value Trap
Price
$3.05
Last close
Models
8/13
Active
VS

PMN

Biotechnology
ProMIS Neurosciences Inc.
Quality
4.2
out of 10
Value Trap
30
LOW
Price
$10.87
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType PLYX Fair ValuePLYX Upside PMN Fair ValuePMN Upside
Bayesian DCF Intrinsic $0.84 -72.4% $6.79 -37.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.19 -93.8% $10.85 -0.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PLYX vs PMN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PLYX vs PMN — Which Stock Is More Undervalued?

PLYX scores higher with a 4.3/10 quality rating vs PMN's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Polaryx Therapeutics, Inc. (PLYX) and ProMIS Neurosciences Inc. (PMN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PLYX currently trades at $3.05 with a QOC of 4.3/10, while PMN trades at $10.87 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).